DeepImmu:
Immunpeptidomics Discovery Service
Our DeepImmu® Immunopeptidomics Discovery Service offers a comprehensive solution to identify and characterise antigens displayed specifically on infected cells or tumors. Understanding the patterns of MHC-peptide presentation is a critical step for the development of immunotherapies and cancer vaccines.
We provide an end-to-end workflow from MHC immunopeptide purification, LC-MS/MS acquisition and data analysis using our AI-powered DeepNovo® algorithm. In addition to sequencing for peptide identification, we provide sequence motif generation, binding affinity and DeepSelf immunogenicity prediction, and strict quality control tests to ensure accurate results.
Request Pricing / Schedule Consultation
Key Service Advantages
- High efficiency and reproducibility of immunopeptide purification
- DeepNovo® algorithm-based sequencing for identifying neoantigens
- Stringent quality control tests and comprehensive reporting
- High quality mass spectrometry data acquisition
- DeepSelf immunogenicity prediction and validation
- Whole service return time of 3 weeks
What we require:
- Frozen cell pellet (>107 cells)
- Species or cell type
- HLA alleles (if known)
What we provide:
- Qualitative results of immunopeptides and corresponding protein information list
- List of all predicted immunopeptides ranked by immunogenicity scores
- QC test results
- Immunopeptide length distribution chart and binding affinity prediction
- Sequence motifs for HLA alleles
- Comprehensive report
References & Resources
References
- Ming Li, Ngoc Hieu Tran, Chao Peng et al. A complete mass spectrometry-based immunopeptidomics pipeline for neoantigen identification and validation, 09 November 2023, PREPRINT (Version 1) available at Research Square